Marshall Wace, LLP Cti Biopharma Corp Transaction History

Marshall Wace, LLP

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	BUY	$4.2 - $6.01 $25 Million - $35.8 Million	5,960,103 New	5,960,103 $25 Million
Q2 2022 Aug 15, 2022	SELL	$3.55 - $6.27 $3.06 Million - $5.41 Million	-862,383 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$1.9 - $5.23 $1.47 Million - $4.04 Million	773,293 Added 867.99%	862,383 $4.03 Million
Q4 2021 Feb 14, 2022	BUY	$1.44 - $2.86 $128,289 - $254,797	89,090 New	89,090 $221,000

Ticker CTIC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 114,385,000
Market Cap $1.04B
Description
CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States. It offers VONJO (pacritinib), an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R for the treatment of adult patients w...

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

Stay updated on Marshall Wace, LLP with notifications on news.